Literature DB >> 11302885

Synchronous chemoradiation for squamous carcinomas.

J S Tobias, D Ball.   

Abstract

Entities:  

Mesh:

Year:  2001        PMID: 11302885      PMCID: PMC1120055          DOI: 10.1136/bmj.322.7291.876

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  12 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.

Authors:  M Saunders; S Dische; A Barrett; A Harvey; D Gibson; M Parmar
Journal:  Lancet       Date:  1997-07-19       Impact factor: 79.321

3.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

4.  A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer.

Authors:  N K Gupta; R C Pointon; P M Wilkinson
Journal:  Clin Radiol       Date:  1987-11       Impact factor: 2.350

5.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 7.  Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors.

Authors:  E E Vokes; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

8.  Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva.

Authors:  S A Wahlen; J D Slater; R J Wagner; W A Wang; E D Keeney; J M Hocko; A King; J M Slater
Journal:  Cancer       Date:  1995-05-01       Impact factor: 6.860

9.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

10.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.

Authors:  C Schaake-Koning; W van den Bogaert; O Dalesio; J Festen; J Hoogenhout; P van Houtte; A Kirkpatrick; M Koolen; B Maat; A Nijs
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

View more
  3 in total

1.  Synchronous chemoradiation for squamous carcinomas. This treatment is not gold standard for lung cancer.

Authors:  F Macbeth; M Saunders
Journal:  BMJ       Date:  2001-08-25

2.  Treatment of oesophageal cancer.

Authors:  J S Tobias
Journal:  J R Soc Med       Date:  2002-01       Impact factor: 18.000

Review 3.  Evolving role of biomaterials in diagnostic and therapeutic radiation oncology.

Authors:  Siyu Shi; Ravi Vissapragada; Joseph Abi Jaoude; Caroline Huang; Anmol Mittal; Elisa Liu; Jim Zhong; Vivek Kumar
Journal:  Bioact Mater       Date:  2020-02-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.